Survodutide results: weight loss, liver fat, Phase 3, and approval status.
Also searched as BI 456906 · glucagon/GLP-1 dual agonist
Survodutide is Boehringer Ingelheim and Zealand Pharma’s investigational once-weekly glucagon/GLP-1 receptor dual agonist. Phase 3 results now span body weight and liver-related measures, but efficacy-estimand maxima, MRI substudy findings, and gastrointestinal discontinuations need to stay attached to their exact populations.
What did the survodutide Phase 3 obesity trial show?
SYNCHRONIZE-1 studied 76 weeks of once-weekly survodutide or placebo in adults with obesity or overweight without type 2 diabetes. The sponsor reported average weight loss of up to 16.6% under the efficacy estimand versus 3.2% with placebo. A prespecified MRI substudy also reported reductions in visceral and liver fat, while gastrointestinal adverse events led to discontinuation in 19.0% of survodutide participants versus 2.9% on placebo. All three pieces belong in a balanced reading of the result.
Compare Survodutide with Retatrutide, without losing the country context.
Put evidence status, ClinicalTrials.gov coverage, official United States records, and qualified US research prices in one view. Blank fields stay blank when the underlying dataset does not support a number.
Investigational clinical program
Official product and seller records attached
Investigational clinical program
What can you conclude about Survodutide today?
These are dated program facts, not a cross-trial ranking, approval forecast, personal treatment recommendation, or proof that a same-name online product is the sponsor's medicine.
An investigational molecule designed to activate glucagon and GLP-1 receptors.
Average loss under the efficacy estimand versus 3.2% with placebo among adults without diabetes.
Sponsor-reported discontinuation due to gastrointestinal events in survodutide versus placebo groups.
At least 30% liver-fat reduction at week 48 versus 24.3% with placebo under the efficacy estimand.
Know which molecule the result belongs to.
- Sponsor
- Boehringer Ingelheim + Zealand Pharma
- Mechanism
- Glucagon + GLP-1 receptor dual agonist
- Route being studied
- Once-weekly subcutaneous injection
- Current stage
- Phase 3 program active and reporting
- Featured trial anchors
- NCT06066515 · NCT06066528 · NCT06077864 · NCT06309992
- Evidence checked
- July 20, 2026
Survodutide weight-loss results, with the trial attached.
This visual shows one selected result, not every dose or endpoint in the program. The percentage remains attached to its duration, population, comparator, analysis method, and source.
Evidence checked July 21, 2026Survodutide reported 16.6% mean reduction at 76 weeks under the efficacy estimand, upper reported result. The comparator recorded 3.2% mean reduction.
Bar lengths share a 0 to 30% visual scale. They describe this selected record and do not make separate trials head-to-head.
- Population
- Adults with obesity or overweight
- Participants
- 726 Actual enrollment in the completed trial record
- Dose
- 6 mg, upper reported result
- Primary analysis
- Efficacy estimand, upper reported result
- Alternate analysis
- Treatment-regimen estimand
- Regulatory status
- Investigational; not FDA approved
Survodutide clinical trials by status, phase, and location.
The current exact-intervention snapshot matches 31 unique NCT records. This chart describes registry coverage and current study fields. It does not compare efficacy, safety, approval probability, eligibility, or treatment access.
Snapshot 2026-07-24Counts use individual locations currently marked Recruiting, not every facility listed on an overall-recruiting study. Repeated centers across studies remain repeated site observations.
What comes after Retatrutide?
Compare Zenagamtide/Amycretin, MariTide, CagriSema, standalone cagrilintide, and survodutide by route, evidence maturity, trial result, and approval status without ranking unrelated studies as one race.
Open the upcoming weight-loss drugs guide →Survodutide across 42 countries.
This profile establishes the program identity and its cited clinical or regulatory record. It does not turn a same-name seller listing into the sponsor’s asset or prove authorization, availability, or lawful supply in another destination.
Compare Survodutide by country →Compare Survodutide by US state →Browse the global peptide country dataset →Is Survodutide approved or available in your country?
Start with the United States FDA record, then check the destination that matters to you. Each country page separates drug identity, authorization, product records, seller claims, and supply rules. Directory checked July 20, 2026.
What the record shows - and what it doesn’t.
Trial percentages are kept beside the design details that make them interpretable. Unknowns stay visible instead of being filled with launch speculation.
SYNCHRONIZE-1 reported Phase 3 efficacy
In adults with obesity or overweight without type 2 diabetes, the 76-week trial reported up to 16.6% average loss under the efficacy estimand versus 3.2% with placebo. ClinicalTrials.gov lists 726 actual participants and a completed record, while the peer-reviewed article is linked from the registry.
Body-composition findings came from a substudy
A prespecified SYNCHRONIZE-1 MRI substudy reported up to 34.0% relative reduction in visceral fat and up to 63.1% relative liver-fat reduction from baseline. Those imaging findings came from participants with measurements at baseline and end of study while on treatment, not automatically from the entire randomized population.
The liver-focused Phase 3 trial met both endpoints
SYNCHRONIZE-MASLD randomized 216 adults in the United States and Spain. At week 48, 84.2% on survodutide versus 24.3% on placebo achieved at least a 30% reduction in MRI-assessed liver fat under the efficacy estimand. Mean weight change was 12.2% versus 1.0%. The treatment-regimen estimates were 68.5% versus 28.6% for the liver-fat threshold and 8.7% versus 1.4% for weight.
Gastrointestinal tolerability is material
The sponsor reported nausea, vomiting, diarrhea, and constipation as the more frequent events compared with placebo. Discontinuation due to gastrointestinal adverse events was 19.0% with survodutide versus 2.9% with placebo in SYNCHRONIZE-1, an important counterweight to efficacy-only summaries.
No marketing approval or final label
Survodutide remains investigational and is not approved for marketing by a regulatory authority. There is no final obesity or liver-disease label, commercial dose, launch date, retail price, pharmacy channel, or insurance policy to compare.
Regulatory timing is not established here
Completed Phase 3 trials, Fast Track designation, Breakthrough Therapy designation, and an active cardiovascular study do not themselves establish a submission date or approval outcome. Those milestones must be documented separately by the sponsor or regulator.
Cross-trial ranking remains invalid
A 16.6% efficacy-estimand maximum cannot be ranked fairly against another program’s result without accounting for population, duration, dose, estimand, adherence, rescue treatment, missing data, and comparator. No head-to-head superiority claim is supported by the sources here.
The questions behind the search.
Concise answers based on the dated sponsor and trial records below. This is educational reporting, not medical advice.
What is survodutide and how does it work?
Survodutide, formerly BI 456906, is an investigational long-acting molecule designed to activate glucagon and GLP-1 receptors. Boehringer Ingelheim is responsible for global development and commercialization under a license from Zealand Pharma. The once-weekly injection is being studied for obesity and overweight, cardiovascular risk, and metabolic liver disease. Its glucagon activity is part of the scientific rationale for liver and metabolic effects, but a mechanism cannot substitute for completed clinical outcomes or regulatory review.
What did the survodutide Phase 3 obesity trial show?
SYNCHRONIZE-1 studied 76 weeks of once-weekly survodutide or placebo in adults with obesity or overweight without type 2 diabetes. The sponsor reported average weight loss of up to 16.6% under the efficacy estimand versus 3.2% with placebo. A prespecified MRI substudy also reported reductions in visceral and liver fat, while gastrointestinal adverse events led to discontinuation in 19.0% of survodutide participants versus 2.9% on placebo. All three pieces belong in a balanced reading of the result.
Is survodutide approved, and is it the same as retatrutide?
Survodutide is not approved for marketing as of this evidence check. It is also not the same molecule as retatrutide: survodutide activates glucagon and GLP-1 receptors, while retatrutide is designed to activate GIP, GLP-1, and glucagon receptors. Their trials use different programs, populations, durations, doses, and analysis methods, so their headline percentages cannot serve as a direct comparison. Neither investigational name should be treated as proof that an online research product is authentic clinical material.
Did survodutide reduce liver fat by 63%?
Two different 63-related findings are easy to confuse. A SYNCHRONIZE-1 MRI substudy reported up to a 63.1% relative reduction in liver fat from baseline among measured participants who remained on treatment. In an earlier Phase 2 MASH trial, 63% of participants in the 2.4 mg group achieved at least a 30% reduction in liver fat; that was a proportion of participants, not a 63% average reduction. The newer Phase 3 SYNCHRONIZE-MASLD trial used the same 30% threshold and reported 84.2% versus 24.3% with placebo under the efficacy estimand.
Do not use an investigational name, trial dose, or online research listing as a substitute for approved care. This page does not recommend treatment, sourcing, or participation in a clinical trial.
Understand the product-category boundary →